ArticleACS infectious diseases2021
Synthesis of Fusidic Acid Derivatives Yields a Potent Antibiotic with an Improved Resistance Profile.
Article in ACS infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Article
- Olefinic side chain modification of fusidic acid enhances anti-MRSA activity and mitigates resistance development.RSC medicinal chemistry · 2025Article
- Multi-Modal Design, Synthesis, and Biological Evaluation of Novel Fusidic Acid Derivatives.Molecules (Basel, Switzerland) · 2025Article
- Exploration of the Fusidic Acid Structure Activity Space for Antibiotic Activity.Molecules (Basel, Switzerland) · 2025Article
- Repurposing fusidic acid as an antimicrobial against enterococci with a low probability of resistance development.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- Imidazoles and Quaternary Ammonium Compounds as Effective Therapies against (Multidrug-Resistant) Bacterial Wound Infections.Antibiotics (Basel, Switzerland) · 2024Article
- The fungal natural product fusidic acid demonstrates potent activity againstAntimicrobial agents and chemotherapy · 2024Article
- Raptinal: a powerful tool for rapid induction of apoptotic cell death.Cell death discovery · 2024Review
- Structures of the Staphylococcus aureus ribosome inhibited by fusidic acid and fusidic acid cyclopentane.Scientific reports · 2024Article
- Article
- Thwarting resistance: MgrA inhibition with methylophiopogonanone a unveils a new battlefront against S. aureus.NPJ biofilms and microbiomes · 2024Article
- Reversing the Natural Drug Resistance of Gram-Negative Bacteria to Fusidic Acid via Forming Drug-Phospholipid Complex.Bioengineering (Basel, Switzerland) · 2024Article
- A review of the fernane-type triterpenoids as anti-fungal drugs.Frontiers in pharmacology · 2024Review
- Article
- The quorum-sensing peptidic inhibitor rescues host immune system eradication: A novel infectivity mechanism.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Mechanistic Studies andJournal of medicinal chemistry · 2022Article
- Antimicrobial Random Peptide Mixtures EradicateAntibiotics (Basel, Switzerland) · 2022Article
- Ligand and structure-based approaches for the exploration of structure-activity relationships of fusidic acid derivatives as antibacterial agents.Frontiers in chemistry · 2022Article
- Bioactivities and Structure-Activity Relationships of Fusidic Acid Derivatives: A Review.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Fusidic acid (FA) is a potent steroidal antibiotic that has been used in Europe for more than 60 years to treat a variety of infections caused by Gram-positive pathogens. Despite its clinical success, FA requires significantly elevated dosing (3 g on the first day, 1.2 g on subsequent days) to minimize resistance, as FA displays a high resistance frequency, and a large shift in minimum inhibitory concentration is observed for resistant bacteria. Despite efforts to improve on these aspects, all previously constructed derivatives of FA have worse antibacterial activity against Gram-positive bacteria than the parent natural product. Here, we report the creation of a novel FA analogue that has equivalent potency against clinical isolates of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.